Nuevas intervenciones en hipertensión arterial pulmonar

The pharmacological management of pulmonary arterial hypertension is based on drugs that act on three main pathways: endothelin 1, prostaglandin I2, and nitric oxide. The majority of clinical studies for the approval of drugs developed to treat this condition have been short and focused on changes in the 6-minute walk test. On taking into account that the different forms of pulmonary arterial hypertension have cell cross-over with the vascular wall as a common denominator for the molecular and cellular changes associated with inappropriate inflammatory and immune processes, imbalance between synthesis and extracellular matrix degradation, genetic (BMPR2 gene in hereditary pulmonary arterial hypertension) and epigenetic alterations, a better understanding of the pathophysiology of the disease is required, which will help in the development of new treatments or interventions in these patients in each one of these levels.